重药控股：2025年1~6月共计提减值准备约3.77亿元

Group 1 - The company announced a provision for asset impairment, which is expected to reduce the net profit attributable to shareholders by approximately 197 million yuan for the first half of 2025 [1][3] - The impairment provision will also correspondingly decrease the equity attributable to shareholders by about 197 million yuan [1][3] - The impairment provision of approximately 377 million yuan was made after an inspection and analysis of various assets within the consolidation scope [3] Group 2 - For the year 2024, the revenue composition of Zhongyao Holdings is as follows: 95.03% from pharmaceutical wholesale, 4.59% from pharmaceutical retail, and 0.38% from other businesses [1]